XML 54 R23.htm IDEA: XBRL DOCUMENT
v3.20.4

Financial Instruments Risk Management | 12 Months Ended
--- | ---
Dec. 31, 2020
Disclosure Of Financial Instruments [Abstract] |
Financial instruments risk management | 17. Financial instruments risk management The Company is exposed to market risk arising from exposure to fluctuation in interest rates and currency exchange rates. These risks are managed by maintaining an appropriate mix of cash deposits in the two main currencies the Company operates in, placed with a variety of financial institutions for varying periods according to expected liquidity requirements. Interest Rate Risk As of December 31, 2020, the Company had cash and cash equivalents of £87.4 million. As of December 31, 2019, the company had cash and cash equivalents of £52.0 million. Exposure to interest rate sensitivity is impacted primarily by changes in the underlying bank interest rates. The Company’s surplus cash and cash equivalents are invested in interest bearing accounts and certificates of deposit from time to time which earn interest at fixed or variable rates based on the terms agreed for each account. The Company has not entered into investments for trading or speculative purposes. Financial assets subject to fixed or variable interest rates are as follows:
|  | 2020 |  |  | 2019 |
|  | (in thousands) |
|  | Carrying amount |  |  | Carrying amount |
|  | £ |  |  | £ |
Financial assets at short-term fixed rates |  |  |  |  |  |  |  |
Cash and cash equivalents |  |  | 48,432 |  |  |  | 41,827 |
Financial assets at variable rates |  |  |  |  |  |  |  |
Cash and cash equivalents |  |  | 5,470 |  |  |  | 7,108 |
Non-interest bearing cash balances |  |  |  |  |  |  |  |
Cash and cash equivalents |  |  | 33,454 |  |  |  | 3,027 |
An increase in the bank interest rates by 0.5 percentage points would increase the net annual interest income applicable to the cash and cash equivalents held on variable and short-term fixed rate deposits by £269,511 (2019: £244,674). Currency Risk The Company’s functional currency is U.K. pounds sterling, and our transactions are commonly denominated in that currency. However, a portion of expenses are incurred in other currencies, primarily U.S. dollars, and are exposed to the effects of this exchange rate. Although the Company is based in the United Kingdom, it sources active pharmaceutical ingredient, raw materials, research and development, manufacturing, consulting and other services worldwide, including from the United States, the European Union and India. Any weakening of the pound sterling against the currencies of such other jurisdictions makes the purchase of such goods and services more expensive for the Company. The Company seeks to minimize this exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to mid-term expenses in these other currencies. The Company thus holds a significant portion of cash and cash equivalents in U.S. dollars and will therefore report the impact of exchange rates movements on these balances. The Company does not use derivative instruments to manage exchange rate exposure. 17. Financial instruments risk management (continued) Financial assets and liabilities in foreign currencies, primarily held in U.S. dollars, are as follows:
|  | 2020 |  |  | 2019 |
|  | (in thousands) |
|  | Carrying amount |  |  | Carrying amount |
|  | £ |  |  | £ |
Financial assets |  |  |  |  |  |  |  |
Prepayments, accrued income and other receivables |  |  | 2,079 |  |  |  | 2,174 |
Current income tax receivable |  |  | 4 |  |  |  | 4 |
Cash and cash equivalents |  |  | 70,419 |  |  |  | 28,980 |
Financial liabilities |  |  |  |  |  |  |  |
Trade payables |  |  | 409 |  |  |  | 549 |
Payroll taxes and social security |  |  | 1 |  |  |  | 18 |
Lease liabilities |  |  | 105 |  |  |  | 52 |
Accrued expenditure |  |  | 926 |  |  |  | 989 |
A 1% increase in the value of the U.K. pound sterling relative to the U.S. dollar would reduce the carrying value of net financial assets and liabilities in foreign currencies by £710,592 (2019: £295,498). Credit risk The Company actively manages cash and cash equivalents across a number of banks and has deposits with different maturity dates. The Company monitors the credit rating of those banks. All of the Company’s cash and cash equivalents at December 31, 2020 were held at U.K. and U.S. financial institutions with short-term A-rated credit ratings, as assessed by recognized international credit rating agencies. As a result, no provision for expected credit losses has been recognized.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfFinancialInstrumentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2020-01-01 -Section Scope -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI -URIDate 2020-01-01 + Details
Name: | ifrs-full_DisclosureOfFinancialInstrumentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration